

\$
0

**For medication
and administration
for SAPHNELO**



Start, Stay, and Save with SAPHNELO

With the SAPHNELO Savings Program, your eligible commercially insured patients can start and stay on SAPHNELO regardless of coverage. Patients may pay as little as \$0 for SAPHNELO and its infusion administration.^{*,†}

If SAPHNELO is approved

If SAPHNELO is approved by insurance, eligible patients may pay as little as **\$0[‡]** for SAPHNELO and its infusion administration.

To be eligible, patients must:

- Have commercial insurance
- Have SAPHNELO approved by their insurance plan

[†]Up to \$16,500 per year for both drug and infusion administration.

If SAPHNELO is denied

If SAPHNELO is denied by insurance, please submit an appeal. If the appeal is denied, patients may be eligible for the SAPHNELO Denied Patient Savings Program where they may pay **\$0** for SAPHNELO and its infusion administration for up to 2 years.[§]

To be eligible, patients must^{||}:

- Have commercial insurance
- Have had their prior authorization (PA) and PA appeal denied by their insurance company
- Have SAPHNELO prescribed for on-label use

[§]Patients who enroll receive support for up to 24 months from the date of initial prescription.

^{||}Full details are included in Terms of Use section on following page.

^{*}Patients are responsible for any cost associated with the infusion administration above the \$150 per infusion administration provided by the program.

[†]Patients who are residents of Massachusetts and Rhode Island are not eligible for infusion administration assistance.

How the SAPHNELO Savings Program Works

The SAPHNELO Savings Program helps eligible commercially insured patients receive SAPHNELO for as little as \$0 out-of-pocket cost for the medication and its infusion administration. Your role in the program will vary, depending on how your practice acquires SAPHNELO.

For either program, please call AstraZeneca Access 360 at **1-866-SAPHNELO (1-866-727-4635)** for complete details.

Specialty Pharmacy—If acquiring SAPHNELO through a Specialty Pharmacy:

Out-of-pocket costs for SAPHNELO	Out-of-pocket costs for infusion administration
For help with out-of-pocket costs for SAPHNELO, patients can sign up for the SAPHNELO Savings Program by signing the support program section of the AstraZeneca Access 360 [™] Enrollment Form.	Patients are responsible for requesting reimbursement for out-of-pocket costs for infusion administration. Reimbursement forms are available by contacting Access 360 at 1-866-SAPHNELO (1-866-727-4635) .

Buy & Bill—If buying SAPHNELO from a Specialty Distributor to administer to your patients:

1. Create an account online at **www.SAPHNELOsavings.com**. This is a one-time registration step and will only take a few minutes.
2. Enroll eligible patients at **www.SAPHNELOsavings.com**.

★ It is highly recommended that you enroll your patients AFTER the PA is approved

- After enrollment, you will receive a letter that contains patient-specific information and instructions on how to submit claims for reimbursement of SAPHNELO and its infusion administration. Please retain this letter for future use
- After administering SAPHNELO, submit a claim to your patient's insurance. You will receive an Explanation of Benefits (EOB) that you can use to determine the exact amount your patient owes for SAPHNELO, including the infusion administration
- Submit request for reimbursement of your patient's out-of-pocket cost of SAPHNELO and its infusion administration at **www.SAPHNELOsavings.com** and include a copy of the EOB. While the out-of-pocket costs for patients will vary, most eligible patients may pay as little as \$0 per infusion of SAPHNELO
- After the SAPHNELO Savings Program claim has been reviewed and approved, you will be notified that the Virtual Debit Card associated with that patient has been loaded with the approved amount. Process a debit card transaction on the registered debit card terminal to retrieve the funds from the card

ELIGIBILITY:

Patients may be eligible for this offer with the following criteria:

- Insured by Commercial insurance with a valid prescription for SAPHNELO® (anifrolumab-fnia) injection for Intravenous infusion, 300 mg AND
- Are a resident of the United States or Puerto Rico AND
- Are not enrolled in a government funded program

Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients who are enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients who are enrolled in a state or federally funded prescription program may not use this program even if they elect to be processed as uninsured (cash-paying). This offer is not insurance.

TERMS OF USE:

Eligible commercially insured patients with a valid prescription for SAPHNELO who enroll in this program may pay as little as \$0 per administration of SAPHNELO dependent upon patient's prescription coverage of SAPHNELO.

SAPHNELO Savings Program—If SAPHNELO is covered by the health plan:

- Up to \$16,500 per calendar year in assistance for out-of-pocket expenses
- The out-of-pocket costs covered by the program can include the cost of the product itself, the cost of infusion administration (program maximum of \$150 per infusion administration).^{*,†}
- Other restrictions may apply. Patient must be enrolled in the program before use. If you have any questions regarding the offer, please call **1-866-SAPHNELO (1-866-727-4635)**.
- Offer is invalid for claims or transactions more than 365 days from the date of service.

Other restrictions apply. Patient is responsible for applicable taxes, if any. Non-transferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed, or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. AstraZeneca reserves the right to rescind, revoke, or amend this offer, eligibility, and terms of use at any time without notice. This offer is not conditioned on any past, present, or future purchase, including refills. Offer must be presented along with a valid prescription for SAPHNELO at the time of purchase. Program covers the cost of the drug, infusion administration,^{*,†} and does not cover the costs for office visits or any other associated costs.

If you meet the Copay Savings program eligibility criteria but SAPHNELO is not covered by your health plan, you may qualify for the Denied Patient Savings Program.

Denied Patient Savings Program Eligibility: Patient must meet all savings program eligibility criteria in addition to the following criteria:

- A Prior Authorization denial and Prior Authorization appeal denial by your health plan are required
- SAPHNELO must be prescribed for on-label use

TERMS OF USE:

Denied Patient Savings Program—If SAPHNELO is NOT covered by the health plan:

- Prescription fills for up to 24 months from the date of the initial prescription
- This program is only administered by approved specialty pharmacies
- Program support includes periodic Benefits Investigation to identify potential changes in patient coverage. If a change in coverage is identified, the prescriber will be contacted to initiate a new Prior Authorization for the patient. If the Prior Authorization is approved, the patient will transition to coverage via their insurance benefits

BY USING THIS PROGRAM, YOU AND YOUR PHARMACIST AND/OR PHYSICIAN UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

^{*}Patients are responsible for any cost associated with the infusion administration above the \$150 per infusion administration provided by the program.

[†]Patients who are residents of Massachusetts and Rhode Island are not eligible for infusion administration assistance.



SAPHNELO is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.

©2023 AstraZeneca. All rights reserved. US-73007 Last Updated 2/23

